| Filed On | Filing |
|---|---|
| 26 Feb 2021 |
8-K/A: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Edesa Biotech, Inc., a company incorporated under the laws of British Columbia, Canada (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 1,562,500 of its comm... |
| 14 Aug 2019 |
8-K/A: Financial Statements and Exhibits
Statements of Operations and Comprehensive Loss – Years Ended December 31, 2018 and 2017 |
| 20 Jun 2019 |
8-K/A: Departure/Election of Directors or Officers; Compensation
THIS AGREEMENT is made as of June 14, 2019, with effect from June 7, 2019 in connection with the closing of the transaction contemplated in the Share Exchange Agreement dated March 7, 2019 (“SEA”). |
| 22 Mar 2016 |
8-K/A: Submission of Matters to a Vote of Security Holders
This Form 8-K/A amends Item 5.07(b) of the Form 8-K filed by Stellar Biotechnologies, Inc. (the “Company”) on March 18, 2016 (the “Original Form 8-K”), which provided the voting results for the proposals submitted to shareholders at the ... |
| 11 Feb 2015 |
8-K/A: Results of Operations and Financial Condition
PORT HUENEME, CA -- (Marketwired - February 09, 2015) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), an importan... |
Loading...